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Introduction
After vascular injury, platelet activation and thrombin generation occur by a reciprocally amplifying mechanism which results in rapid thrombus formation. As fibrin formation occurs, the fibrinolytic system becomes activated to promote fibrin dissolution. However, the role of platelets in fibrinolysis is not clearly understood. Platelets can support and localize fibrinolysis by facilitating clot retraction (1) (2) (3) (4) , binding plasminogen, and potentiating plasminogen activation (5) . Plasmin may also affect platelet function. Streptokinase injection into rabbits causes transient thrombocytopenia, prolongation of the bleeding time, in vivo platelet degranulation and release, and inhibition of the in vitro aggregation response to collagen (6) . Platelets when infused into rabbits, presumably because of plasmininduced alterations in platelet membrane glycoproteins (7) . Furthermore, the shortening of platelet survival during continuous vessel wall injury in the rat can be reversed by the antifibrinolytic agent epsilon aminocaproic acid (8) . Recently, we have shown that plasmin treatment of platelets in vitro leads to a loss of platelet membrane glycoprotein Ib, a surface receptor for von Willebrand's factor, with an associated inhibition of ristocetin-induced platelet agglutination (9) . Previous in vitro studies on the direct effects of plasmin on platelet function have shown that high concentrations of plasmin stimulate aggregation and release, and that prolonged exposure of platelets to plasmin results in inhibition of thrombin-and collagen-induced aggregation (6, 10) . These results have been considered to indicate that plasmin induces the release of and then the digestion of platelet fibrinogen, causing a subsequent loss of platelet sensitivity to aggregating agents (6) .
This study investigates in detail the function of human platelets exposed to human plasmin and, specifically, examines for the first time the effects of plasmin on platelet arachidonic acid metabolism. We have found that plasmin, at concentrations considerably lower than previously studied, causes a dose-and time-dependent inhibition of platelet aggregation which is associated with a marked impairment of thromboxane formation. Plasmin was found to specifically inhibit endogenous arachidonic acid mobilization from platelet membrane phospholipid pools.
Methods
Preparation of platelets. Venous blood anticoagulated with 13 mM sodium citrate was obtained from volunteers who had not ingested aspirin or other medications known to interfere with platelet function for at least 10 d before donation. Blood was centrifuged at 160 g for 10 min to obtain platelet-rich plasma (PRP)'. Platelets were separated from plasma by gel filtration by applying PRP to a column of Sepharose 2B. The platelets were eluted with a modified Tyrode's buffer containing 130 mM NaCl, 9 mM sodium bicarbonate, 6 mM dextrose, 10 mM sodium citrate, 10 (12) . Gel-filtered suspensions of platelets were incubated with plasmin at 370C in a shaking water bath as described below. At the end of the appropriate preincubation periods, plasmin was inactivated with aprotinin before the addition of a stimulating agent (throm-1. Abbreviations used in this paper: CU, caseinolytic units; HPLC, high-performance liquid chromatography; PGE1 and PGI2, prostaglandins El and 12; PRP, platelet-rich plasma; TIU, trypsin inhibitor units; TXB2, thromboxane B2. bin, ionophore A23187, collagen, or arachidonate). The concentration of aprotinin added was always in excess of the amount needed to totally inhibit plasmin activity as determined in an S-2288 chromogenic substrate assay following the manufacturer's method (13). The assay was performed at 370C in a spectrophotometer equipped with a recording chart (model 2400; Gilford Instrument Laboratories, Inc., Coming Glass Works, Oberlin, OH). Kinetic data supplied by the manufacturer indicate that, for a substrate concentration of 1 X 10-3 mol/liter and a plasmin concentration of 4 X l0-9 mol/liter, AA/min at 405 nm is 0.042. One CU plasmin equals -0.45 nmol plasmin. Aprotinin was likewise added before platelet stimulation in control reactions that were preincubated with no plasmin.
Platelet aggregation. Aliquots of 0.4 ml of gel-filtered platelets were added to cuvettes containing CaC12 (3 mM, final concentration). Aggregation was monitored using a standard nephelometric method (14) in a dual-channel aggregometer (Payton Associates, Inc., Buffalo, NY).
Platelet serotonin release. PRP was incubated with 3.4 4M ['4C]serotonin, gel-filtered, and serotonin release was measured by a modification of the method of Jerushalmy and Zucker (15) . Reactions were terminated with formalin (1.5%, final concentration) to stop further release or re-uptake of serotonin (16) . Samples were immediately centrifuged at 8,700 g for 3 min in a microfuge (model B; Beckman Instruments, Inc., Spinco Div., Palo Alto, CA), and supernatants were counted for released radioactivity.
Radioimmunoassay of thromboxane B2 (TXB2). Immediately after 4-min reactions with the appropriate stimuli, platelet suspensions were centrifuged at 8,700 g for 3 min. The amount of TXB2 in the supernatants was determined by standard radioimmunoassay with phosphate-gelatin buffer (50 mM potassium biphosphate, 0.14 M NaCl, and 0.1% gelatin, pH 7.4), a 1:2,000 dilution of TXB2 antiserum, and 10,000 dpm [3H]TXB2. After overnight incubation at 4°C, charcoalcoated dextran was used to separate antibody-bound from unbound radioligand.
Oxygen consumption. Polarographic measurements were made with an oxygen monitor (model 53; Yellow Springs Instrument Co., Yellow Springs, OH) equipped with a Clark-type oxygen sensor (model 5331; Yellow Springs Instrument Co.). The electrode was fitted to a waterjacketed cell (OX-15253; Gilson Medical Electronics, Middleton, WI) connected to a circulator (K-2/RD; Lauda Div., Brinkmann Instruments, Inc., Westbury, NY) maintained at 37°C. At 37°C, a 0.13 M NaCI solution was assumed to contain 400 nAtoms 02/ml at equilibrium with room air. Full-scale deflection of the instrument was adjusted to correspond to this 02 content (17) .
Release of [3H]arachidonic acid. PRP (5.5 ml) was incubated for 15 min at 37°C with 6.25 MCi [3H]arachidonic acid bound to 10% bovine serum albumin (essentially fatty acid free), thus permitting maximal incorporation of [3H]arachidonic acid into platelet membrane phospholipids, as described by Rittenhouse-Simmons et al. (18) . The labeled PRP was gel-filtered to remove unincorporated [3H]arachidonic acid. After appropriate additions (plasmin and/or thrombin or ionophore A23187, as described below), the reacted platelet suspensions were pelleted by centrifugation at 8,700 g for 3 min, and radioactivity released into the supernatant was counted.
High-performance liquid chromatography (HPLC) separation of arachidonic acid metabolites. In some experiments, the supernatants of the [3Hlarachidonic acid release reactions were acidified to pH 3.0 with citric acid and extracted three times with ethyl acetate. After evaporating the pooled ethyl acetate extracts under N2, the entire sample was injected in 50 Mtl of methanol into a 4.6 X 250 mm Ultrasphere ODS 5-Mum reverse-phase HPLC column (Altex Scientific, Inc., Berkeley, CA). All platelet arachidonic acid metabolites were separated as previously described (19) , using increasing proportions of acetonitrile (30.5-95%) in aqueous phosphoric acid (pH 2.0). The flow rate was 1.0 ml/min. The column was equilibrated with 30.5% acetonitrile for 40 min before reuse. HPLC pumps (model 510; Waters Instruments Inc., Rochester, MN) with a programmable gradient system controller and a lambda-max LC spectrophotometer (model 481; Waters Instruments, Inc.) were used, and arachidonic acid metab-olites were measured by collection of 1.0-ml fractions for radioactivity. Nonradioactive standards of TXB2 and 12-hydroxy-5,8,10,14-eicosatetraenoic acid were run simultaneously as elution markers.
Platelet cyclic AMP. Cyclic AMP in platelets was measured by 
Results
Plasmin effect on platelet aggregation. Platelet aggregation in response to thrombin (1-5 U/ml), calcium ionophore A23187 (3.5 gM), and collagen (12.5 ,g/ml) was inhibited after preincubation of platelets with plasmin for 20 min at 37°C. This plasmin-induced inhibition of platelet aggregation was dosedependent ( Fig. 1) , with complete inhibition noted at plasmin concentrations of 0.1-0.5 CU/ml. In contrast, preincubation of platelets with plasmin at concentrations up to 0.5 CU/ml did not inhibit arachidonate-induced aggregation. There was only a slight dampening of the platelet aggregation response to arachidonate at 0.5 CU/ml plasmin. As shown in Fig. 2 , the inhibition of thrombin-induced platelet aggregation by plasmin was also time-dependent, with complete inhibition of aggregation achieved within 10 min of plasmin preincubation at 37°C. In contrast, plasmin preincubation for as long as 60 min had a minimal effect on arachidonate-induced aggregation. Because high concentrations of plasmin have been previously reported to induce platelet aggregation and release (6) , we examined the direct effect of plasmin on platelet activation. At concentrations up to 0.5 CU/ml, plasmin alone did not directly stimulate platelet shape change, aggregation, or serotonin release.
Plasmin effect on platelet thromboxane synthesis. The production of platelet thromboxane (measured by radioimmunoassay of TXB2) stimulated by thrombin, ionophore A23 178, and collagen was blocked by preincubation of platelets with plasmin (Table I ). The plasmin inhibition of TXB2 synthesis was clearly noted at concentrations above 0.05 CU/ ml. Plasmin maximally inhibited thrombin-induced TXB2 production by 95%, although it maximally inhibited ionophoreinduced release by only 58%; the extent of inhibition of collagen-induced TXB2 production was intermediate. The concentration-dependent inhibitory effects of plasmin on platelet aggregation and TXB2 formation in response to these three agents were approximately parallel. In contrast, consistent with its lack of effect on arachidonate-induced aggregation, plasmin at concentrations up to 0.5 CU/ml did not inhibit arachidonateinduced TXB2 production (Table I) Plasmin effect on platelet arachidonic acid release. The discrepancy between plasmin's inhibition of thrombin-, ionophore-, and collagen-induced aggation and TXB2 production and its lack of inhibition of arachidonate-induced aggregation and TXB2 production suggests that plasmin may exert its by blocking mobilization of endogenous arachidonic om platelet membrane phospholipid pools. To examine )ssibility, we studied the effect of plasmin on platelet consumption. The platelet oxygen burst is entirely a )n of arachidonic acid oxygenation (20, 21) . When Gel-filtered platelets were preincubated with various concentrations of plasmin (0-0.5 CU/ml) for 20 min at 370C. After the addition of aprotinin (1.7 TIU/ml), TXB2 production was stimulated by thrombin (I U/ml), ionophore A23187 (3.5 WM), collagen (12.5 pg/ml), or arachidonate (0.38 mM). TXB2 was measured by radioimmunoassay of supernatants of 4-min reactions with these agents. Data are mean±SEM of quadruplicate measurements representing two experiments.
stimulated by thrombin, ionophore, or collagen, the platelet oxygen burst depends on both endogenous arachidonic acid release by phospholipases and the actual oxygen consuming arachidonic acid oxygenases; when directly stimulated by exogenous arachidonate, the platelet oxygen burst is an index of oxygenation only (22) . As shown in Fig. 3 , plasmin preincubation almost entirely abolished the thrombin-induced platelet oxygen burst (from a maximal rate of 20 nAtoms/min in the control reaction to 3 nAtoms/min in the plasmintreated reaction). In contrast, plasmin had no effect on the arachidonate-induced oxygen burst (13 nAtoms/min in both the control and plasmin-treated reactions). Figure 3 . Effect of plasmin on platelet oxygen consumption. Gelfiltered platelets were preincubated with (0.1 CU/ml) or without plasmin for 20 min at 37°C. After the addition of aprotinin (1.7 TIU/ml), the oxygen burst was initiated at the points of the arrows by thrombin (2 U/ml) or arachidonate (50 MM). The slope of declining oxygen content in the chamber before stimulus addition represents basal oxygen consumption. Aprotinin alone did not inhibit the oxygen burst.
To directly demonstrate the inhibitory effect of plasmin on arachidonic acid mobilization, platelets were incubated with [3Hfarachidonic acid to label membrane phospholipid pools and then stimulated with thrombin or ionophore A23 187 to induce arachidonic acid release. As shown in Table II , plasmin preincubation inhibited the thrombin-induced release of arachidonic acid by -50%. However, ionophore-induced arachidonic acid release was not inhibited by plasmin.
When the metabolic products of the thrombin-induced release of arachidonic acid were analyzed by HPLC, the formation of cyclooxygenase and lipoxygenase metabolites were found to be comparably affected by plasmin. Plasmin preincubation reduced the formation of [3H]TXB2 (the major cyclooxygenase metabolite) by 75.4% and 12-hydroxy-5,8,10,14eicosatetraenoic acid (the major lipoxygenase metabolite) by 64.2%.
Since these results suggest that plasmin inhibits platelet function and arachidonic acid metabolism by blocking endogenous arachidonic acid mobilization, the effects of plasmin on platelet cyclic AMP were determined. As shown in Table III , prostaglandin 12 (PGI2) and prostaglandin El (PGEI), known stimulators of platelet adenylate cyclase and inhibitors of arachidonic acid release, raised cyclic AMP concentrations approximately sixfold over basal levels; this effect was markedly enhanced by the phosphodiesterase inhibitor theophylline. However, plasmin failed to raise platelet cyclic AMP even in the presence of theophylline.
Discussion
In this study, we report that plasmin causes a doseand timedependent inhibition of platelet aggregation in response to thrombin, calcium ionophore, and collagen, but not in response to arachidonic acid. These functional effects are paralleled by inhibitory effects of plasmin on net platelet thromboxane production. Plasmin is found to exert this action, at least in part, by blocking the mobilization of endogenous arachidonic acid from platelet membrane pools without inhibiting the further metabolism of free arachidonic acid.
Platelet aggregation depends upon the binding of fibrinogen to surface receptors (23) . The inhibition of platelet aggregation by plasmin at the low concentrations used in this study is unlikely to be due to plasmin-induced release of platelet fibrinogen and its subsequent digestion by plasmin (6) . Almost complete inhibition of platelet aggregation was found in response to thrombin, ionophore, and collagen by plasmin at concentrations that did not directly affect shape change, aggregation, or release. Furthermore, plasmin was unlikely to have its effect on extracellular fibrinogen, since washed platelets suspended in fibrinogen-free buffer were used. Plasmin did not digest fibrinogen released from platelets after stimulation by thrombin, ionophore, or collagen, since plasmin was completely inactivated with aprotinin before addition of the aggregating agent. Aprotinin itself had no effect on platelet aggregation. Finally, plasmin pretreatment at these lower concentrations did not inhibit arachidonate-induced platelet aggregation. If plasmin degradation of fibrinogen were the mechanism of its inhibitory action on platelets, it would also be expected to block arachidonate-induced aggregation. Patients with Glanzmann's thrombasthenia, whose platelets lack surface receptors for fibrinogen, demonstrate a markedly impaired aggregation response to arachidonate as well as to the other aggregating agents (24) . Therefore, the mechanism of plasmin inhibition of platelet aggregation observed in our studies is unlikely to be due to the digestion of fibrinogen by plasmin. Paralleling the plasmin dose-dependent inhibition of platelet aggregation, we found marked inhibition of platelet thromboxane production in response to thrombin, ionophore, and collagen. In contrast, as with its lack of effect on arachidonateinduced aggregation, plasmin failed to inhibit arachidonateinduced thromboxane formation. The discrepancy between thrombin, ionophore, and collagen responses on the one hand and arachidonate response on the other, suggested that plasmin may exert its inhibitory effect on mobilization of endogenous arachidonic acid from platelet membrane phospholipid pools. This was confirmed by two additional experimental approaches. First, plasmin was found to almost completely block the thrombin-induced platelet oxygen burst, which depends on both endogenous arachidonic acid release by thrombin and its subsequent oxygenation. In contrast, plasmin had no effect on the arachidonate-induced oxygen burst, which is an index of oxygenation only (21) . Second, we directly examined the effect of plasmin on the thrombin-induced hydrolysis of free arachidonic acid after labeling platelet membrane phospholipids with [3H]arachidonic acid. Plasmin inhibited arachidonic acid release by -50% but did not inhibit the subsequent metabolism of arachidonic acid by either the cyclooxygenase or the lipoxygenase pathway. It is of interest that, while plasmin pretreatment of the platelets inhibited thrombin-induced arachidonate release, it did not affect ionophore-induced release. The inhibitory effect of plasmin on thrombin-induced TXB2 production was also more marked than on ionophore-induced TXB2 production (Table I ). These data suggest that the effect of plasmin on arachidonic acid mobilization may be a complex one, possibly inhibiting thrombin-activated phosphatidylinositol-specific phospholipase C preferentially over an effect on ionophore A23187-activated phospholipase A (25) .
Our data suggest that plasmin inhibits platelet function, at least in part, by blocking the mobilization of arachidonic acid from membrane phospholipids in response to phospholipase activators. Plasmin may exert its effect either by the inactivation of platelet phospholipase(s) or by the depletion of precursor pools of arachidonic acid esterified to membrane phospholipids. The latter mechanism has been noted in thrombin-treated platelets, in which a reduction of the arachidonic acid content of phosphatidylinositol has been found (26, 27) . This has been proposed as a likely explanation for the finding of decreased thromboxane formation from endogenous arachidonic acid in thrombin-pretreated platelets (28) . In this latter study, cyclooxygenase activity of thrombin-treated platelets was preserved, similar to our observations with plasmin-treated platelets. Furthermore, since the plasmin-inhibited platelet activities noted in this study are calcium-dependent, it is possible that plasmin also exerts its inhibitory effects on platelets by impairing the membrane binding or translocation of free calcium.
Since platelet arachidonic acid mobilization is inhibited by agents that raise intracellular levels of cyclic AMP (29, 30), we examined the effect of plasmin on platelet cyclic AMP content.
Unlike known activators of adenylate cyclase (PGI2 and PGE,), plasmin failed to increase platelet cyclic AMP, even in the presence of a phosphodiesterase inhibitor, precluding this action as the mechanism of plasmin inhibition of arachidonic acid mobilization.
The important question of whether the concentration of plasmin found to inhibit platelet function and arachidonic acid metabolism in our studies is attainable in pathologic or pharmacologic states of fibrinolysis is difficult to resolve. Alpha-2-antiplasmin is the major physiologic inhibitor of plasmin, and it acts rapidly to bind and inactivate any free plasmin that may be released into the plasma. However, in severe liver disease or disseminated intravascular coagulation and during thrombolytic therapy with streptokinase, alpha-2antiplasmin is consumed, and biologically active plasmin circulates (31) (32) (33) . More important, the amounts of free plasmin generated locally at the site of clot formation are likely to be the critical modulators of platelet function. Plasmin molecules bound to fibrin and involved in fibrin degradation are protected from rapid inactivation by alpha-2-antiplasmin (34) but could still be effective in inhibiting platelets. Activation of plasmin on the surface of the injured vessel wall could also have localized effects on platelets in its proximity (8) . Finally, enhanced and locally concentrated plasmin may generate on the surfaces of activated platelets that bind plasminogen within thrombi (5) .
Conceptually, in a manner analogous to the reciprocal activation of thrombin and platelets to promote clot formation at sites of vascular injury, plasmin and platelets may interact to promote and amplify clot dissolution. Considerably more in vitro and in vivo studies are required to elucidate these complex interactions. This study suggests the possibility that local plasmin generation may inhibit the further accrual of platelets into a developing thrombus. Therefore, platelets may be important targets of physiologic, pathologic, and pharmacologic fibrinolysis.
